• Explore /
  • Poster
  • / Axitinib with or without dose titration for first-line metastatic renal cell carcinoma (mRCC): Unblinded results from a randomized phase II study.

Axitinib with or without dose titration for first-line metastatic renal cell carcinoma (mRCC): Unblinded results from a randomized phase II study.

Abstract Poster

Authors

Brian Rini

Brian I. Rini

Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

Brian I. Rini , Viktor Gruenwald , Mayer N. Fishman , Bohuslav Melichar , Takeshi Ueda , A. H. Bair , Ying Chen , Paul W. Bycott , Dmitri Pavlov , Sinil Kim , Eric Jonasch

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2013 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session C: Renal Cancer

Track

Renal Cell Cancer

Sub Track

Renal Cell Cancer

Clinical Trial Registration Number

NCT00835978

Citation

J Clin Oncol 31, 2013 (suppl 6; abstr LBA349)

DOI

10.1200/jco.2013.31.6_suppl.lba349

Abstract #

LBA349

Poster Bd #

B2

Abstract Disclosures

Similar Posters

First Author: Brian I. Rini

First Author: Yoshihiko Tomita

First Author: Mehul Gupta

First Author: Joseph Vento